Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB
Published in New England Journal of Medicine
Methodology
Multicenter randomized double-blind placebo (mineral oil)-controlled trial of icosapent ethyl 4 g/day in statin-treated patients with elevated triglycerides
Key Findings
Primary composite endpoint occurred in 17.2% of icosapent ethyl vs 22.0% of placebo patients (HR 0.75, 95% CI 0.68-0.83, p<0.001); cardiovascular death was reduced by 20%.
Conclusions
High-dose purified EPA substantially reduced ischemic events in high-risk statin-treated patients with elevated triglycerides.
Limitations
Mineral-oil placebo may have raised event rates in the control arm; results apply to high-dose prescription EPA, not typical fish-oil doses; higher rates of atrial fibrillation and bleeding.
Supplements Studied
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo.
Outcomes Measured
The risk of ischemic events was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo.
Primary composite endpoint occurred in 17.2% of icosapent ethyl vs 22.0% of placebo patients (HR 0.75, 95% CI 0.68-0.83, p<0.001); cardiovascular death was reduced by 20%.
The risk of ischemic events was significantly lower among those who received icosapent ethyl than among those who received placebo.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Amarin Pharma
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.